Investor Relations

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.

The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.

PLAC Test Fact Sheet - January 2014 PDF

Lp-PLA2 Fact Sheet - January 2014 PDF

Heart Failure Fact Sheet - March 2014 PDF

View all »   RSSRecent Releases

Nov 5, 2014
diaDexus, Inc. Reports Third Quarter 2014 Financial Results

Oct 29, 2014
diaDexus, Inc. to Report Third Quarter 2014 Financial Results on November 5, 2014



 

©2014 diaDexus, Inc. | diaDexus and PLAC are U.S. Registered Trademarks of diaDexus, Inc.